Laura Sepp-Lorenzino is CSO & VP at Intellia Therapeutics, Inc. (NTLA). They have made 6 open-market trades across 1 company since 2021, most recently 2026-06-01.
CIK 0001777421
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NTLA | SELL | 2025-01-03 | 2025-01-07 | $12.18 | $218K | -17.4% | -15.9% | -45.7% |
| NTLA | SELL · 10b5-1 | 2024-01-08 | 2024-01-10 | $28.87 | $66K | -8.4% | +0.3% | -7.4% |
| NTLA | SELL | 2024-01-03 | 2024-01-05 | $29.46 | $326K | -10.4% | -11.9% | -11.4% |
| NTLA | SELL | 2023-01-04 | 2023-01-06 | $37.72 | $339K | -13.2% | +14.3% | -6.3% |
| NTLA | SELL | 2022-01-01 | 2022-03-03 | $112.25 | $129K | -16.9% | +8.7% | -38.9% |
| NTLA | SELL | 2021-08-30 | 2021-09-01 | $154.82 | $30.0M | -6.3% | -18.4% | -30.0% |
| NTLA | SELL | 2021-08-04 | 2021-08-06 | $138.24 | $7.2M | -7.1% | -0.5% | -18.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.